BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
September 12, 2024 16:56 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
Integra diventa il primo Itron Engage Sales Channel Partner in Italia
June 12, 2024 08:45 ET
|
Itron, Inc.
LIBERTY LAKE, Wash., June 12, 2024 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), che propone modalità innovative per le Aziende per la distribuzione dell’energia (Utilitiies) e le Municipalità per...
Integra Becomes First Itron Engage Sales Channel Partner in Italy
June 12, 2024 08:45 ET
|
Itron, Inc.
Integra S.R.L. to help utilities and cities in Italy enhance their grid infrastructure with Itron’s solutions.
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
February 27, 2024 15:52 ET
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 14:40 ET
|
BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
Autonomous Mobile Manipulator Robots Market worth $2,099.63 Million by 2030 - Exclusive Report by The Insight Partners
August 28, 2023 09:21 ET
|
The Insight Partners
Pune, India, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The adoption of AMMR is increasing owing to the rise in automation in the warehouse and manufacturing industries. Further, the rise in demand for chips...
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
August 28, 2023 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023 07:30 ET
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...